Global ADME-Toxicology Testing Industry

Sep 08, 2011, 06:59 ET from Reportlinker

NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global ADME-Toxicology Testing Industry

http://www.reportlinker.com/p0611076/Global-ADME-Toxicology-Testing-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnosti

This report analyzes the worldwide markets for ADME-Toxicology Testing in US$ Million by the following Product Segments: Toxicology Testing (In-Vivo, & In-Vitro), and ADME Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 83 companies including many key and niche players such as Accelrys, Inc., ACEA Biosciences, Inc., Agilent Technologies, Inc., Albany Molecular Research, Inc., Aureus Sciences, Bayer Technology Services GmbH, BD Biosciences, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Caliper Life Sciences, Inc., Cambridge Cell Networks Ltd., CeeTox, Inc., Cellartis AB, Celsis International Ltd., Cerep SA, CompuDrug International, Inc., Cyprotex PLC, Entelos, Inc., Galapagos NV, Life Technologies Corporation, Molecular Discovery Ltd., MultiCASE, Inc., Noray Bioinformatics S.L., Optivia Biotechnology, Pharmaron, Inc., Promega Corporation, Qualyst, Inc., Simulations Plus, Inc., Sirius Analytical Instruments Ltd., Taconic Farms, Inc., Tecan Group Ltd., Thermo Fisher Scientific, Inc., and Xceleron, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

ADME-Tox - An Introduction 3

Toxicology Testing 4

ADME Testing 4

Absorption 4

Distribution 4

Metabolism 4

Excretion 5

2. INDUSTRY OVERVIEW 6

ADME-Tox Testing Gains Traction 6

Table 1: Leading Causes of Failure During New Drug

Development: Percentage Share Breakdown by ADME/Tox Issues,

Insufficient Efficacy, Adverse Side Effects, and Commercial

Viability (includes corresponding Graph/Chart) 6

Current and Future Analysis 7

Pharma Industry Renews Focus on Cost Optimization 7

Table 2: US R&D Productivity Trends in Pharma Industry (2000-

2010) (includes corresponding Graph/Chart) 8

China and India: Hot Spots for R&D Investment 8

Table 3: Percentage Breakup of Global R&D Spending by Region

(2009) (includes corresponding Graph/Chart) 9

CROs Expand Presence 9

Growing Need for Collaborations 10

3. MARKET DYNAMICS 11

Trends and Technologies Shaping the ADME/Tox Market 11

Growing Inclination Towards In-vitro Assays for Toxicology

Studies 11

Focus Shifts to Innovative Approaches 11

Increasing Use of Cell-Based Assays over Other Methods in

Toxicity Testing 11

Functional Assays: An Effective Way of Predicting Specific

Toxic Effects 12

Introduction of Early In Vitro ADMET Studies 12

Stem Cells in Drug Discovery 13

Primary Hepatocytes Become Standard Tool for Evaluation in

Hepatic Metabolism 13

3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing 13

In Silico ADME-Tox Growing at a Fast Clip 13

Factors Hindering Growth 14

Cardiotoxicity Testing Gains Prominence 14

Computational Models on Rise 14

Adoption of Data Management Systems 15

Drug Transporter Analysis Becoming Part of ADME Assessment 15

Regulatory Bodies Focus on Transporter Mediated DDIs 15

4. DRUG DISCOVERY & DEVELOPMENT 16

Table 4: Escalating Costs of New Drug Development Over the

Decades (includes corresponding Graph/Chart) 16

Drug Discovery and Development 17

Target identification 17

Target Validation 17

Lead Identification 18

Lead Optimization 18

Pre-Clinical Testing 19

Clinical Trials 19

Drug Discovery Technologies 20

Innovation in Screening Guarantees Success for Drug Discovery

Programs 20

5. PRODUCT OVERVIEW 21

ADME-Tox - An Introduction 21

Absorption 21

Distribution 21

Metabolism 21

Excretion 22

Toxicity 22

ADME-Tox Profiling 22

ADME-Tox Screening Technologies 22

ADME-Tox Parameters 23

Cell Based Assays 24

Liver Cell Based Assays 24

Intestinal Cell Based Assays 24

Kidney Cell Based Assays 24

6. PRODUCT LAUNCHES/INNOVATIONS/ REGULATORY APPROVALS 25

Simulations Plus to Develop Predictive QSAR Toxicity Models in

Partnership with FDA 25

BIOCIUS Life Sciences Extends Contract Research Services

Range, Introduces New ADME Assay Analysis 25

LGC Unveils reinnervate's 3D Cell Culture Scaffold, Alvetex®

for In Vitro Toxicity Testing for Drug Discovery 25

Cyprotex Unveils Cyprotox®, In Vitro Toxicology Services 25

Absorption System Rolls Out Express Plus ADME Assays 26

LGC Standards Unveils ADME Toxicology Guide for New Drug

Discovery 26

Absorption System Secures Patent for BCP Knockdown Cell Line

in CellPort Technologies Brand 26

Cyprotex Relaunches CellCiphr™ Toxicity Panels 26

Sigma® Life Science Launches New Models of Knockout Rats for

ADME-Tox Applications 27

Hudson Robotics Unveils VaryScreen ADME-Tox Workstation 27

Agilent Technologies Rolls Out RF360 High Resolution System

for High-Throughput Screening of In Vitro ADME Assays 27

MultiCell Technologies Receives Patent for EA1C-35 and Fa2N-4

Immortalized Human Hepatocyte Cell Lines 28

Cyprotex Unveils Web Portal for Providing Access to Drug

Discovery Services 28

Applied Biosystems/MDS Analytical Technologies Launches

DiscoveryQuant™ Software 28

BioTrove Releases RapidFire 300 System for High-Throughput

Screening 28

CXR Biosciences and Millipore Launch ToxReporter™ 29

7. RECENT INDUSTRY ACTIVITY 30

CIT and Stemina Ink Strategic Partnership Deal for

Distribution of Toxicity Assay and New Technology Development 30

Hamner forms Research Initiative for Development of 3D Tissue

Bioassays for Toxicity Testing 30

Aureus Pharma Becomes Aureus Sciences and Unveils Extensive

Life Sciences Application Web Portal 30

CeeTox Purchases ADMETRx's Assets 30

Phytopharm to Receive Chemistry and ADME Services Support from

O2h 31

Life Technologies Inks Licensing Agreement with Biopredic

International for HepaRG® Cells 31

O2h to Provide ADME Services to Sentinel Oncology 31

Galapagos Takes Over Argenta Discovery, Becomes Leading Drug

Discovery Services Provider 31

BioFocus to Offer ADME Services as Part of Extended

Partnership Deal with Chisei 31

Cyprotex to Take Over Apredica and Cellumen 32

Optivia and UCSF Receive SBIR Grant for Development of ADME

Systems 32

Accelrys Merges with Symyx 32

Lonza Group Purchases Simbiosys Biowares India Pvt Ltd 33

Gentronix and Apredica Collaborate for Predictive Toxicology

Services 33

AsisChem Joins Forces with Apredica for Drug Discovery Support

Services 33

Batelle Ventures Funds Hepregen's Spin-Off from MIT 34

ADMETRx and CeeTox Enter into Partnership to Provide Extensive

ADME-Tox Services 34

Promega and Celsis IVT Ink Agreement to Collaborate for ADME-

Tox Testing in Primary Hepatocytes 34

Pharma Algorithms and ACD/Labs Collaborate to Enhance In

Silico Prediction and Screening 35

8. FOCUS ON SELECT GLOBAL PLAYERS 36

Accelrys, Inc. (US) 36

ACEA Biosciences, Inc. (US) 36

Agilent Technologies, Inc. (US) 36

Albany Molecular Research, Inc. (US) 37

Aureus Sciences (France) 37

Bayer Technology Services GmbH (Germany) 37

BD Biosciences (US) 38

Beckman Coulter, Inc. (US) 38

Bio-Rad Laboratories, Inc. (US) 38

Caliper Life Sciences, Inc. (US) 39

Cambridge Cell Networks Ltd. (UK) 39

CeeTox, Inc. (US) 39

Cellartis AB (Sweden) 40

Celsis International Ltd. (US) 40

Cerep SA (France) 40

CompuDrug International, Inc. (US) 40

Cyprotex PLC. (US) 41

Entelos, Inc. (US) 41

Galapagos NV (Belgium) 41

Life Technologies Corporation (US) 41

Molecular Discovery Ltd (UK) 42

MultiCASE, Inc. (US) 42

Noray Bioinformatics S.L. (Spain) 42

Optivia Biotechnology 42

Pharmaron, Inc. (US) 43

Promega Corporation (US) 43

Qualyst, Inc. (US) 43

Simulations Plus, Inc. (US) 43

Sirius Analytical Instruments Ltd (UK) 44

Taconic Farms, Inc. (US) 44

Tecan Group Ltd. (Switzerland) 44

Thermo Fisher Scientific, Inc. (US) 44

Xceleron, Inc. (UK) 45

9. GLOBAL MARKET PERSPECTIVE 46

Table 5: World Recent Past, Current & Future Analysis for ADME-

Tox Testing by Geographic Region - US, Canada, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Revenue Figures in US$ Million for Years 2008 Through

2017 (includes corresponding Graph/Chart) 46

Table 6: World 10-Year Perspective for ADME - Tox Testing by

Geographic Region - Percentage Breakdown of Dollar Revenues

for US, Canada, Japan, Europe, and Rest of World Markets for

Years 2008, 2011 & 2017 (includes corresponding Graph/

Chart) 47

Table 7: World Recent Past, Current & Future Analysis for

Toxicology Testing by Geographic Region - US, Canada, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Revenue Figures in US$ Million for Years 2008 Through

2017 (includes corresponding Graph/Chart) 48

Table 8: World 10-Year Perspective for Toxicology Testing by

Geographic Region - Percentage Breakdown of Dollar Revenues

for US, Canada, Japan, Europe, and Rest of World Markets for

Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 49

Table 9: World Recent Past, Current & Future Analysis for

Toxicology Testing by Sub-Segment - In-Vivo and In-Vitro

Testing Markets Independently Analyzed with Annual Revenue

Figures in US$ Million for Years 2008 Through 2017 (includes

corresponding Graph/Chart) 50

Table 10: World 10-Year Perspective for Toxicology Testing by

Sub-Segment - Percentage Breakdown of Dollar Revenues for

In-Vivo and In-Vitro Testing Markets for Years 2008, 2011 &

2017 (includes corresponding Graph/Chart) 50

Table 11: World Recent Past, Current & Future Analysis for

In-Vivo Toxicology Testing by Geographic Region - US, Canada,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Revenue Figures in US$ Million for Years

2008 Through 2017 (includes corresponding Graph/Chart) 51

Table 12: World 10-Year Perspective for In-Vivo Toxicology

Testing by Geographic Region - Percentage Breakdown of Dollar

Revenues for US, Canada, Japan, Europe, and Rest of World

Markets for Years 2008, 2011 & 2017 (includes corresponding

Graph/Chart) 52

Table 13: World Recent Past, Current & Future Analysis for

In-Vitro Toxicology Testing by Geographic Region - US, Canada,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Revenue Figures in US$ Million for Years

2008 Through 2017 (includes corresponding Graph/Chart) 53

Table 14: World 10-Year Perspective for In-Vitro Toxicology

Testing by Geographic Region - Percentage Breakdown of Dollar

Revenues for US, Canada, Japan, Europe, and Rest of World

Markets for Years 2008, 2011 & 2017 (includes corresponding

Graph/Chart) 54

Table 15: World Recent Past, Current & Future Analysis for

ADME Testing by Geographic Region - US, Canada, Japan, Europe,

and Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2008 Through 2017

(includes corresponding Graph/Chart) 55

Table 16: World 10-Year Perspective for ADME Testing by

Geographic Region - Percentage Breakdown of Dollar Revenues

for US, Canada, Japan, Europe, and Rest of World Markets for

Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 56

10. THE UNITED STATES 57

A.Market Analysis 57

Current and Future Analysis 57

Clinical Trials Market in the US 57

Product Launches/Regulatory Approvals 57

Strategic Corporate Developments 60

Select Players 63

B.Market Analytics 71

Table 17: US Recent Past, Current & Future Analysis for ADME-

Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro)

and ADME Markets Independently Analyzed with Annual Revenues

in US$ Million for Years 2008 Through 2017 (includes

corresponding Graph/Chart) 71

Table 18: US 10-Year Perspective for ADME - Tox Testing by

Segment - Percentage Breakdown of Dollar Revenues for

Toxicology (In-Vivo and In-Vitro) and ADME Markets for Years

2008, 2011 & 2017 (includes corresponding Graph/Chart) 72

11. CANADA 73

A.Market Analysis 73

Strategic Corporate Development 73

B.Market Analytics 74

Table 19: Canadian Recent Past, Current & Future Analysis

for ADME - Tox Testing by Segment - Toxicology (In-Vivo and

In-Vitro) and ADME Markets Independently Analyzed with

Annual Revenues in US$ Million for Years 2008 Through 2017

(includes corresponding Graph/Chart) 74

Table 20: Canadian 10-Year Perspective for ADME - Tox

Testing by Segment - Percentage Breakdown of Dollar Revenues

for Toxicology (In-Vivo and In-Vitro) and ADME Markets for

Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 75

12. JAPAN 76

Market Analysis 76

Table 21: Japanese Recent Past, Current & Future Analysis

for ADME - Tox Testing by Segment - Toxicology (In-Vivo and

In-Vitro) and ADME Markets Independently Analyzed with

Annual Revenues in US$ Million for Years 2008 Through 2017

(includes corresponding Graph/Chart) 76

Table 22: Japanese 10-Year Perspective for ADME - Tox

Testing by Segment - Percentage Breakdown of Dollar Revenues

for Toxicology (In-Vivo and In-Vitro) and ADME Markets for

Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 77

13. EUROPE 78

A.Market Analysis 78

Current and Future Analysis 78

Clinical Trials Market in Europe 78

Product Launches/Regulatory Approvals 78

Strategic Corporate Developments 79

Select Players 81

B.Market Analytics 84

Table 23: European Past, Current & Future Market Analysis

for ADME - Tox Testing by Country/Geographic Region -

France, Germany, Italy, UK, and Rest of Europe Markets

Independently Analyzed with Annual Revenues in US$ Million

for Years 2008 through 2017 (includes corresponding

Graph/Chart) 84

Table 24: European Recent Past, Current & Future Analysis

for ADME - Tox Testing by Segment - Toxicology (In-Vivo and

In-Vitro) and ADME Markets Independently Analyzed with

Annual Revenues in US$ Million for Years 2008 Through 2017

(includes corresponding Graph/Chart) 85

Table 25: European 10-Year Perspective for ADME - Tox

Testing by Country/Geographic Region - Percentage Breakdown

of Dollar Sales for France, Germany, Italy, UK, and Rest of

Europe Markets for Years 2008, 2011 & 2017 (includes

corresponding Graph/Chart) 86

Table 26: European 10-Year Perspective for ADME - Tox

Testing by Segment - Percentage Breakdown of Dollar Revenues

for Toxicology (In-Vivo and In-Vitro) and ADME Markets for

Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 87

13a. FRANCE 88

Market Analysis 88

Table 27: France Recent Past, Current & Future Analysis for

ADME - Tox Testing by Segment - Toxicology (In-Vivo and

In-Vitro) and ADME Markets Independently Analyzed with

Annual Revenues in US$ Million for Years 2008 Through 2017

(includes corresponding Graph/Chart) 88

Table 28: French 10-Year Perspective for ADME - Tox Testing

by Segment - Percentage Breakdown of Dollar Revenues for

Toxicology (In-Vivo and In-Vitro) and ADME Markets for Years

2008, 2011 & 2017 (includes corresponding Graph/Chart) 89

13b. GERMANY 90

Market Analysis 90

Table 29: German Recent Past, Current & Future Analysis for

ADME - Tox Testing by Segment - Toxicology (In-Vivo and

In-Vitro) and ADME Markets Independently Analyzed with

Annual Revenues in US$ Million for Years 2008 Through 2017

includes corresponding Graph/Chart) 90

Table 30: German 10-Year Perspective for ADME - Tox Testing

by Segment - Percentage Breakdown of Dollar Revenues for

Toxicology (In-Vivo and In-Vitro) and ADME Markets for Years

2008, 2011 & 2017 (includes corresponding Graph/Chart) 91

13c. ITALY 92

Market Analysis 92

Table 31: Italian Recent Past, Current & Future Analysis for

ADME - Tox Testing by Segment - Toxicology (In-Vivo and

In-Vitro) and ADME Markets Independently Analyzed with

Annual Revenues in US$ Million for Years 2008 Through 2017

(includes corresponding Graph/Chart) 92

Table 32: Italian 10-Year Perspective for ADME - Tox Testing

by Segment - Percentage Breakdown of Dollar Revenues for

Toxicology (In-Vivo and In-Vitro) and ADME Markets for Years

2008, 2011 & 2017 (includes corresponding Graph/Chart) 93

13d. THE UNITED KINGDOM 94

Market Analysis 94

Table 33: The UK Recent Past, Current & Future Analysis for

ADME - Tox Testing by Segment - Toxicology (In-Vivo and

In-Vitro) and ADME Markets Independently Analyzed with

Annual Revenues in US$ Million for Years 2008 Through 2017

(includes corresponding Graph/Chart) 94

Table 34: The UK 10-Year Perspective for ADME - Tox Testing

by Segment - Percentage Breakdown of Dollar Revenues for

Toxicology (In-Vivo and In-Vitro) and ADME Markets for Years

2008, 2011 & 2017 (includes corresponding Graph/Chart) 95

13e. REST OF EUROPE 96

A.Market Analysis 96

Russia 96

Table 35: Russian Clinical Trials Market (2009): Percentage

Breakdown by Trial Type - Global Multi- center Clinical

Trials, Local Clinical Trials (Foreign Sponsors), Local

Clinical Trials (Local Sponsors), Bioequivalence studies

(Foreign Sponsors), and Bioequivalence Studies (includes

corresponding Graph/Chart) 96

Table 36: Russian Clinical Trials Market (2008): Percentage

Breakdown by Hosting Countries - Russia, USA, Germany, UK,

Switzerland, and Others (includes corresponding

Graph/Chart) 97

Table 37: Number of Clinical Trials in Russia by Study

Phase (2008) (includes corresponding Graph/Chart) 97

Spain 97

Garnering Investments from Multinational Pharma Companies 97

Phase III Clinical Trials Engross Maximum R&D Expenditure 97

Table 38: Apportion of R & D Expenditure by Study Phase in

Spain: 2008 (includes corresponding Graph/Chart) 98

B.Market Analytics 98

Table 39: Rest of Europe Recent Past, Current & Future

Analysis for ADME - Tox Testing by Segment - Toxicology

(In-Vivo and In-Vitro) and ADME Markets Independently

Analyzed with Annual Revenues in US$ Million for Years 2008

Through 2017 (includes corresponding Graph/Chart) 98

Table 40: Rest of Europe 10-Year Perspective for ADME - Tox

Testing by Segment - Percentage Breakdown of Dollar Revenues

for Toxicology (In-Vivo and In-Vitro) and ADME Markets for

Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 99

14. REST OF WORLD 100

A.Market Analysis 100

Current and Future Analysis 100

Asia: The Most Preferred Destination for Clinical Trials 100

India 100

A Thriving Clinical Trials Market 100

Table 41: Cost of Conducting Clinical Trials: India Vs.

US (In US$ Million) (includes corresponding Graph/Chart) 101

Latin America: An Emerging Market for Clinical Trials 101

Table 42: Latin American Clinical Trials Market by Country

(2009): Percentage Share Breakdown for Brazil, Mexico,

Argentina, Chile, Peru, Colombia, Costa Rica, Guatemala,

and Panama (includes corresponding Graph/Chart) 102

Strategic Corporate Development 102

B.Market Analytics 103

Table 43: Rest of World Recent Past, Current & Future

Analysis for ADME - Tox Testing by Segment - Toxicology

(In-Vivo and In-Vitro) and ADME Markets Independently

Analyzed with Annual Revenues in US$ Million for Years 2008

Through 2017 (includes corresponding Graph/Chart) 103

Table 44: Rest of World 10-Year Perspective for ADME - Tox

Testing by Segment - Percentage Breakdown of Dollar Revenues

for Toxicology (In-Vivo and In-Vitro) and ADME Markets for

Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 104

COMPETITIVE LANDSCAPE

Total Companies Profiled: 83 (including Divisions/Subsidiaries - 87)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 53

Canada 2

Japan 1

Europe 21

France 4

Germany 4

The United Kingdom 13

Spain 3

Rest of Europe 6

Asia-Pacific (Excluding Japan) 1

------------------------------------------

To order this report:

Diagnostics Industry: Global ADME-Toxicology Testing Industry

Diagnostics Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com